Therapeutic Feeding for Severe Acute Malnutrition in a 1-Year-Old
This 1-year-old child with severe acute malnutrition (5 kg at 70 cm represents approximately 50% weight-for-height) should be immediately enrolled in a therapeutic feeding program and started on F-75 formula at 150 kcal/kg/day (750 kcal total) with 3 g protein/kg/day during the stabilization phase for 2-7 days, followed by transition to ready-to-use therapeutic food (RUTF) during rehabilitation. 1, 2
Initial Assessment and Classification
This child meets criteria for severe acute malnutrition (SAM) based on weight-for-height being well below 70% of median (approximately -3 Z-score). The child requires therapeutic feeding program (TFP) enrollment, which is a medical intervention designed to save lives and restore nutritional health 2.
Stabilization Phase (Days 1-7)
F-75 Formula Administration
- Caloric target: 150 kcal/kg/day = 750 kcal/day for this 5 kg child
- Protein target: 3 g/kg/day = 15 g/day 2
- Formula composition: F-75 provides 75 kcal per 100 mL with 0.9 g protein per 100 mL 1
- Volume needed: Approximately 1000 mL/day of F-75
- Feeding frequency: 4-6 meals per day, ideally around-the-clock if possible 2
Feeding Method
Given the child's age and likely poor appetite (common in SAM), continuous nasogastric tube feeding should be initiated if oral intake is inadequate, as this lowers resting energy expenditure and is necessary in severely malnourished infants 3. The child may require nasogastric feedings for short intervals under trained supervision 2.
Critical Supportive Measures on Day 1
- Vitamin A: Full course upon admission (100,000 IU for age 12 months) 2
- Measles immunization: Check status and administer if needed 2
- Mebendazole: Should NOT be given as child is under 12 months 2
- Monitor for hypoglycemia and hypocalcemia: Correct immediately 4
Fluid Management
Start conservatively at 75-90 mL/kg/day (375-450 mL/day for this child) given the severe malnutrition and risk of fluid overload 3. This can be liberalized to 95-150 mL/kg/day as clinical status improves.
Rehabilitation Phase (After Stabilization)
Transition Criteria
Once the child shows clinical improvement (typically 2-7 days):
- Appetite returns
- No signs of acute illness
- Tolerating feeds without complications
RUTF Administration
Transition to ready-to-use therapeutic food (RUTF), which contains milk powder, sugar, peanut butter, vegetable oil, vitamins, and minerals 1. RUTF can be administered at home, which is more effective than clinic-based treatment, especially in resource-limited settings 1.
Monitoring Requirements
Daily Initially
- Weight: Daily during stabilization, then twice weekly 2
- Target weight gain: 10 g/kg/day (50 g/day for this child) 2
- Clinical status: Activity level, appetite, signs of edema or illness
Ongoing Assessment
- Maintain detailed patient register with identification bracelet and ration card 2
- Follow up any missed visits at home 2
- Monitor for complications including aspiration risk with tube feeding 3
Discharge Criteria from TFP
Transfer to supplementary feeding program when:
- Child maintains 80% weight-for-height (Z-score of -2) for 2 weeks
- Weight gain without edema
- Active and free from obvious illness
- Good appetite established 2
For this 5 kg child at 70 cm, target weight would be approximately 8 kg before discharge from therapeutic feeding.
Critical Pitfalls to Avoid
Do not delay feeding while awaiting complete diagnostic workup. Severely malnourished children have poor appetites and may appear to refuse food—this is expected and requires nasogastric support, not withholding nutrition 2.
Avoid rapid fluid administration in the initial phase. These children are at high risk for fluid overload and cardiac failure. Start conservatively at 75-90 mL/kg/day 3.
Do not use standard infant formulas initially. The metabolic derangements in SAM require the specific low-protein, controlled-energy composition of F-75 during stabilization 1.
Monitor for refeeding syndrome: Electrolyte requirements are 4-7 mEq/kg/day sodium and 2-4 mEq/kg/day potassium, but must be individualized based on clinical monitoring 3.